Higher expression levels of SLC1A5 or MTHFD2 were associated with poorer OS and relapse-free survival (RFS), advanced tumor stages, and increased likelihood of lymph node metastasis in KIRC patients. Here, MTHFD2 is linked to metastatic malignant neoplasm in the lymph nodes.